A.M.S. Business Summary

Anti-Microbial Savior BioteQ Co., Ltd. (A.M.S.) operates a dual-track business model centered on its proprietary ExtrO™ extraction technology, which it leverages to develop high-value antimicrobial compounds for the pharmaceutical, medical device, and agricultural sectors. The company generates revenue through a combination of product sales—primarily its SIPSIP™ series of advanced wound dressings and MEDIACE™ antibacterial ingredients—and an "early licensing" strategy for its drug pipeline, including the antiviral candidate AMS-2140. Its business is divided into three primary segments: Drug Development, which utilizes an AI-driven screening platform for infectious diseases; Medical Devices, focused on FDA-approved wound care solutions; and Agricultural Technology, featuring the SeepPlug™ degradable substrate for soil conservation. A.M.S. competes with local and international players such as ACRO Biomedical, Medigen Biotechnology, and Think Bioscience; it distinguishes itself by applying medical-grade extraction techniques to diverse industrial applications, positioning itself as a versatile biotechnology integrator in the Asia-Pacific market. The company was founded in 2018 by George (Yi-Ju) Tsai, who serves as Chairman and Chief Technology Officer. Tsai, a specialist in plant pathology from National Chung Hsing University, is the primary architect of the ExtrO™ technology that underpins the company's entire product portfolio. The executive leadership is further strengthened by CEO Calvin Wei, a seasoned financial strategist with an MBA from California State Polytechnic University and a distinguished pedigree in venture capital, having previously served as the Chairman of Taiwan Venture Capital and a director of the Taipei Exchange (TPEx). The R&D and quality control divisions are led by Vice President Ian Chang, Ph.D., an expert in pharmaceutical innovation from National Taiwan University. The board of directors is notable for its stability and deep industry ties, featuring members with extensive experience in Taiwan’s regulatory and financial sectors, which has been instrumental in the company’s successful transition from the Emerging Stock Market to its current standing on the TPEx.